Clinical resourceProfessional clinical guidance
- Source type
- Clinical resource
- Access type
- Publisher
- Publisher
- Viral Vitalism
- Added
- 2026-06-27
Trust profile
82
Professional clinical guidance
- Publisher type
- Professional guidance
- Bias profile
- Moderate
Best used for
- Clinical context
- Practice guidance
Weak for
- Replacing primary evidence
Used in Viral Vitalism
Supporting evidencebrief1 reference
FDA Reopened a Path for a One-Time Hunter Syndrome Gene Therapy
Roles: Supporting evidence
Show section-level references
Claims supported
No reusable evidence claims are currently attached to this source.
Related studies
No structured study record is currently attached to this source.
Related sources
GovernmentU.S. health regulator
FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease
Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 2 connections
ArticleGeneral published source
Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission
Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.
- Trust score
- 60
- Publisher
- Regenxbio
- Access
- Publisher
- Usage
- 1 connection
ArticleGeneral published source
Reuters: FDA reverses course on Regenxbio rare-disease gene therapy
Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 2 connections
ArticleGeneral published source
Reuters: UniQure to seek approval for Huntington therapy after FDA U-turn
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 1 connection
Topic tags
medicineregenerative-medicinegene-therapyrare-diseaseregulatory-watchregenxbionavsunlirgx-121hunter-syndrome